文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

含利福平或利福喷丁的结核病预防治疗方案完成率、安全性与疗效:个体患者数据网络荟萃分析

Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
PubMed 文献 · Lancet Respir Med · 2023-03-23
一句话结论个体患者数据网络荟萃分析提示,3HP方案完成率高于4R方案,但不良事件风险更高,选择方案时需权衡完成率与安全性。

该研究通过检索PubMed 2000年1月1日至2019年3月1日发表的随机对照试验,采用个体患者数据网络荟萃分析方法,比较3个月每周利福喷丁联合异烟肼(3HP)与4个月每日利福平(4R)方案的完成率、安全性和结核病发病率。共纳入6项试验、14个国家、17572名参与者。结果显示3HP完成率高于4R(aRR 1.06,95%CI 1.02-1.10;aRD 0.05,95%CI 0.02-0.07),但3HP因不良事件导致停药的风险更高(任何严重程度aRR 2.86,95%CI 2.12-4.21;3-4级aRR 3.46,95%CI 2.09-6.17),两组结核病发病率无差异。作者认为在选择结核病预防治疗方案时需权衡完成率与安全性。

要点

  • 3HP方案治疗完成率高于4R方案(aRR 1.06,95%CI 1.02-1.10;aRD 0.05,95%CI 0.02-0.07)。
  • 3HP方案因不良事件导致停药的风险高于4R:任何严重程度aRR 2.86(95%CI 2.12-4.21),aRD 0.03(95%CI 0.02-0.05)。
  • 3HP方案3-4级不良事件导致停药风险高于4R:aRR 3.46(95%CI 2.09-6.17),aRD 0.02(95%CI 0.01-0.03)。
  • 3HP与4R方案结核病发病率无差异。
  • 作者认为选择结核病预防治疗方案时需权衡完成率与安全性,研究结果尚待证实。

适用人群与场景

  • 纳入比较3HP或4R与6个月或9个月异烟肼方案、并报告治疗完成、不良事件或结核病发病率的随机对照试验的个体患者数据。
  • 共纳入6项试验、14个国家、17572名参与者。

研究设计与关键结果

  • 研究类型:个体患者数据网络荟萃分析,检索PubMed 2000年1月1日至2019年3月1日发表的随机对照试验。
  • 纳入6项试验、14个国家、17572名参与者。
  • 治疗完成率:3HP高于4R(aRR 1.06,95%CI 1.02-1.10;aRD 0.05,95%CI 0.02-0.07)。
  • 因治疗相关不良事件导致停药(任何严重程度):3HP风险高于4R(aRR 2.86,95%CI 2.12-4.21;aRD 0.03,95%CI 0.02-0.05)。
  • 因治疗相关不良事件导致停药(3-4级):3HP风险高于4R(aRR 3.46,95%CI 2.09-6.17;aRD 0.02,95%CI 0.01-0.03)。
  • 其他不良事件定义下3HP风险同样升高,且在各年龄组中一致。
  • 3HP与4R的结核病发病率无差异。

证据类型、等级与局限

  • 证据类型:个体患者数据网络荟萃分析(基于随机对照试验)。
  • 作者指出,在缺乏直接比较随机对照试验的情况下,本网络荟萃分析提示3HP完成率高于4R但不良事件风险更高。
  • 局限:作者认为研究结果尚待证实(Although findings should be confirmed)。

对床旁实践的改变

  • 作者认为,在选择结核病预防治疗方案时,必须考虑完成率与安全性之间的权衡。
  • 3HP方案完成率高于4R,但因不良事件导致停药的风险更高,临床选择时需结合患者情况权衡。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: 3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment. As these regimens have not been compared directly, we used individual patient data and network meta-analysis methods to compare completion, safety, and efficacy between 3HP and 4R.

METHODS: We conducted a network meta-analysis of individual patient data by searching PubMed for randomised controlled trials (RCTs) published between Jan 1, 2000, and Mar 1, 2019. Eligible studies compared 3HP or 4R to 6 months or 9 months of isoniazid and reported treatment completion, adverse events, or incidence of tuberculosis disease. Deidentified individual patient data from eligible studies were provided by study investigators and outcomes were harmonised. Methods for network meta-analysis were used to generate indirect adjusted risk ratios (aRRs) and risk differences (aRDs) with their 95% CIs.

FINDINGS: We included 17 572 participants from 14 countries in six trials. In the network meta-analysis, treatment completion was higher for people on 3HP than for those on 4R (aRR 1·06 [95% CI 1·02-1·10]; aRD 0·05 [95% CI 0·02-0·07]). For treatment-related adverse events leading to drug discontinuation, risks were higher for 3HP than for 4R for adverse events of any severity (aRR 2·86 [2·12-4·21]; aRD 0·03 [0·02-0·05]) and for grade 3-4 adverse events (aRR 3·46 [2·09-6·17]; aRD 0·02 [0·01-0·03]). Similar increased risks with 3HP were observed with other definitions of adverse events and were consistent across age groups. No difference in the incidence of tuberculosis disease between 3HP and 4R was found.

INTERPRETATION: In the absence of RCTs, our individual patient data network meta-analysis indicates that 3HP provided an increase in treatment completion over 4R, but was associated with a higher risk of adverse events. Although findings should be confirmed, the trade-off between completion and safety must be considered when selecting a regimen for tuberculosis preventive treatment.

TRANSLATIONS: For the French and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Winters N, Belknap R, Benedetti A, et al. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023. PMID: 36966788. doi:10.1016/S2213-2600(23)00096-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。